Rosy  Wills

Rosy Wills

Followers 0
Following 0
A number of key players are competing against each other to expand their existing customer base.Getinge Group (Sweden), Medtronic plc (Ireland), and LivaNova PLC (U.K.) are the top three players of the extracorporeal membrane oxygenation (ECMO) machine market.These players jointly accounted for a share of 65% to 70% of the total ECMO machine market in 2015.Know more: Group is the largest player in the global market.The company offers its ECMO products under its Maquet brand.The company also develops innovative products such as CARDIOHELP system which is a portable heart-lung support system in the market.Moreover, in September 2015, the company partnered with iMDsoft GmbH (Germany) to offer clinical information systems to reduce the documentation process time of heart-lung machines, blood/gas monitors, and heater-cooler units.
According to the new market research report eHealth Market is expected to reach USD 132.35 Billion by 2023 from USD 47.60 Billion in 2018, at a CAGR of 22.7%.Factors driving market growth include the regulatory mandates and government initiatives for the implementation of eHealth solutions; growing mHealth, telehealth, and remote patient monitoring markets; and increasing need to curtail the escalating healthcare costs.In addition, the emerging market in China, India, and Australia; rising shift towards patient-centric healthcare delivery; and growing use of eHealth solutions in outpatient care facilities are further increasing the demand for eHealth solutions and services.Speak to Analyst: 2017, the eHealth solutions segment accounted for the largest share of the eHealth market.The eHealth solutions segment will continue to dominate the eHealth market, mainly due to the high demand of eHealth solutions due to the benefit of improved patient safety and patient care, stringent regulations, increasing government initiatives supporting the growth of these solutions, and the need to improve the efficiency of healthcare services by reducing medical errors.Healthcare consumers are expected to register the highest CAGR during the forecast period.The growth in this end-user segment can be attributed to the factors such as the increasing number of people requiring remote patient monitoring, rising demand for personalized care, and high penetration of digital technologies in the healthcare industry.In 2017, North America dominated the global eHealth market.The large share of this regional segment can be attributed to the region’s favorable regulatory scenario, the high adoption of eHealth solutions to curtail soaring healthcare costs, regulatory requirements regarding patient safety, and the presence of a large number of healthcare IT companies.Get Sample Pages: MethodologyTop-down and bottom-up approaches were used to validate the size of the global eHealth market and estimate the size of various other dependent submarkets.Major players in the market were identified through secondary sources secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource, journals and associations such as American Health Information Management Association, Ohio Health Information Management Association and their market revenues were determined through primary and secondary research.
According to the new market research report Defibrillators Market is projected to reach USD 10,883.3 million by 2022 from USD 9,323.5 million in 2017 at a CAGR of 3.1%. Factors such as technological advancements in defibrillators, increasing burden of target diseases, growing focus on providing public-access defibrillators, and rising number of training & awareness programs on defibrillators are driving the growth of this market.Read More: The report analyzes the global market by product, end user, and region.The implantable cardioverter defibrillators (ICDs) segment is expected to account for the largest share of the defibrillators market, by product type, in 2017On the basis of products, the market is classified into implantable cardioverter defibrillators (ICDs) and external defibrillators. The ICDs product segment is bifurcated into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs). The T-ICDs segment is further classified into single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy defibrillators (CRT-Ds). The external defibrillators segment is further classified into manual external defibrillators, automated external defibrillators (AEDs), and wearable cardioverter defibrillators (WCDs).This report covers the defibrillators market data across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global market in 2017, followed by Europe. The large share in the North American region is mainly attributed to the rising incidence of target diseases in the region, technological advancements in defibrillators, and increasing number of public defibrillation programs in the region. Factors such as the rapidly growing aging population, increasing cases of cardiovascular diseases, improving research infrastructure, and growing focus of key market players to expand their presence in this region are driving the growth of the Asia Pacific market.Download PDF Brochure: North America dominated the global defibrillators market in 2017The large share of the North American market can mainly be attributed to the continuous technological advancements and product innovations, increasing number of public defibrillation programs, and rising focus of key players to expand their business in the North American region.ZOLL Medical (US) held the leadership position in the global external defibrillators market. The company adopted new product launches, agreements, and partnerships as its core business strategies to enhance its share in the global external market. Other prominent players in the global external market included Philips (Netherlands), Physio-Control (US), Cardiac Science (US), Nihon Kohden (Japan), SCHILLER (Switzerland), Mindray Medical (China), Mediana (South Korea), METRAX (Germany), and METsis (Turkey).Contact:Mr. Shelly SinghMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: [email protected]
According to the new market research report Spinal Implants Market is expected to reach USD 17.27 billion by 2021, growing at CAGR of 5.3% during the forecast period.Technological advancements in spine surgery devices, and increasing aging and obese population with increasing number of spine deformities, and rising demand for minimally invasive spine surgery procedures are the key factors fuelling the growth of the spinal surgery devices market.Read More: Motion preservation/non-fusion technology segment to grow at fastest rate during the forecast period.On the basis of technology, the global spinal implants market is segmented into three categories, namely, spinal fusion and fixation, vertebral compression fracture treatment, spinal decompression, and motion preservation/non-fusion technologies.The motion preservation/non-fusion segment is expected to grow at the highest CAGR in the next five years, owing to the development of technologically advanced non-fusion devices and rising demand for minimally invasive surgical procedures among patients.The spinal fusion and fixation technology segment has been further divided into two categories, namely, fusion and fixation.The motion preservation/non-fusion technologies segment is further categorized into dynamic stabilization, artificial disc replacement, annulus repair, and disc nucleus replacement.Based on the type of product, the spinal implants market is classified into seven segments, namely, thoracic fusion and lumbar fusion devices, cervical fusion devices, spine biologics, vertebral compression fracture treatment devices, non-fusion treatment devices, spinal decompression devices, and spine bone stimulators.
According to research report the global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2%.Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body.Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer.They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids.They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.Read More: Based on cancer type, the breast cancer segment accounted for the largest share of the market in 2016The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers, such as cervical, multiple myeloma, and CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers.Next generation sequencing (NGS)Sequencing is the process of determining the precise order of nucleotides in a DNA/RNA sample.The advent of rapid sequencing methods has greatly enhanced biological and medical research and the discovery of biomarkers.